Bafetinib analog, Lyn-IN-1 - CAS# 887650-05-7 clozanide Doxorubicin is released from the

Doxorubicin is released from the albumin carrier after cleavage of the acid-sensitive hydrazone linker within the acidic environment of tumors and

developed to overcome all-trans retinoic acid (ATRA) resistance

Molecular Weight: 197

Pulsatilla saponin D (SB365)

Cardamonin is a modulator of STAT3 activation in prostate cancer

Bafetinib analog, Lyn-IN-1 - CAS# 887650-05-7 clozanide Doxorubicin is released from theBafetinib, also known as INNO 406 and NS187, is an orally bioavailable 2 phenylaminopyrimidine derivative with potential antineoplastic activity. Bafetinib specifically binds to and inhibits the Bcr Abl fusion protein tyrosine kinase, an abnormal enzyme produced by Philadelphia chromosomal translocation associated with chronic myeloid leukemia (CML). This agent also inhibits the Src family member Lyn tyrosine kinase, upregulated in imatinib resistant